2026 Ann C. Collier: Immunology Researcher – H-Index, Publications & Awards

Discipline name	D-Index	World Ranking	Current World Ranking	National Ranking	Current National Ranking	Publications	Citations
Immunology	97	810	740	455	409	383	40479
Medicine	97	9173	8614	4732	4379	393	40484

Overview

Ann C. Collier is affiliated with the University of Washington in the United States. Their research primarily centers on breast cancer, with a focus on advanced breast cancer therapies and cancer treatment pharmacology. The scope of their work also includes investigations into HER2/EGFR in cancer research, estrogen and related hormone effects, cancer genomics and diagnostics, breast cancer treatment studies, and BRCA gene mutations in cancer.

Their publication record includes studies published across several prominent venues:

Annals of Oncology
Journal of Clinical Oncology
Cancer Research
npj Breast Cancer
Clinical Cancer Research

Main fields of study include Medicine and Biochemistry, Genetics and Molecular Biology, highlighting a multidisciplinary approach to cancer research. Subfields addressed in their work encompass Pulmonary and Respiratory Medicine, Oncology, Cancer Research, and Genetics.

Recent papers authored or coauthored by Ann C. Collier are:

"CDK4/6i-treated HR+/HER2- breast cancer tumors show higher ESR1 mutation prevalence and more altered genomic landscape," 2024, npj Breast Cancer
"Interim analyses (IA) of the giredestrant (G), G + abemaciclib (A), and G + ribociclib (R) arms in MORPHEUS Breast Cancer (BC): A phase I/II study of G treatment (tx) combinations in patients (pts) with estrogen receptor-positive, HER2-negative locally advanced/metastatic BC (ER+, HER2- LA/mBC)," 2023, Journal of Clinical Oncology
"An Open-label Phase I Study of GDC-0927 in Postmenopausal Women with Locally Advanced or Metastatic Estrogen Receptor-Positive Breast Cancer," 2023, Clinical Cancer Research
"365P Interim analysis (IA) of the giredestrant (G) + samuraciclib (SAMURA) arm in MORPHEUS breast cancer (BC): A phase I/II study of G treatment (tx) combinations in patients (pts) with oestrogen receptor-positive (ER+), HER2-negative, locally advanced/metastatic BC (LA/mBC)," 2024, Annals of Oncology
"395P Interim analysis (IA) of the giredestrant (G) + ipatasertib (IPAT) arm in MORPHEUS Breast Cancer (BC): A phase I/II study of G treatment (tx) combinations in patients (pts) with oestrogen receptor-positive (ER+), HER2-negative, locally advanced/metastatic BC (LA/mBC)," 2023, Annals of Oncology

Frequent coauthors contributing to these studies include:

Heather M. Moore
Joohyuk Sohn
Jorge Martinalbo
Mafalda Oliveira
Kyung Hae Jung

Best Publications

HIV-associated neurocognitive disorders persist in the era of potent antiretroviral therapy: CHARTER Study.

R. K. Heaton;D. B. Clifford;D. R. Franklin;S. P. Woods

2697
Citations
HIV-associated neurocognitive disorders before and during the era of combination antiretroviral therapy: differences in rates, nature, and predictors

Robert K. Heaton;Donald R. Franklin;Ronald J. Ellis;J. Allen McCutchan

1805
Citations
Effect of early versus deferred antiretroviral therapy for HIV on survival.

Mari M. Kitahata;Stephen J. Gange;Alison G. Abraham;Barry Merriman

1623
Citations
Antiretroviral-Drug Resistance among Patients Recently Infected with HIV

Susan J. Little;Sarah Holte;Jean Pierre Routy;Eric S. Daar

1565
Citations
Clinical and epidemiologic features of primary HIV infection.

Timothy W Schacker;Ann C. Collier;James Hughes;Theresa Shea

1295
Citations
Treatment of human immunodeficiency virus infection with saquinavir, zidovudine, and zalcitabine. AIDS Clinical Trials Group.

Ann C. Collier;Robert W. Coombs;David A. Schoenfeld;Roland L. Bassett

1062
Citations
Validation of the CNS Penetration-Effectiveness rank for quantifying antiretroviral penetration into the central nervous system.

Scott Letendre;Jennifer Marquie-Beck;Edmund Capparelli;Brookie Best

1005
Citations
Highly active antiretroviral therapy decreases mortality and morbidity in patients with advanced HIV disease.

Edward L. Murphy;Ann C. Collier;Leslie A. Kalish;Susan F. Assmann

805
Citations
The prevalence and incidence of neurocognitive impairment in the HAART era.

Kevin R. Robertson;Marlene Smurzynski;Thomas D. Parsons;Kunling Wu

804
Citations
Plasma Viremia in Human Immunodeficiency Virus Infection

Robert W. Coombs;Ann C. Collier;Jean-P. Allain;Beverly Nikora

797
Citations
Invasion of the central nervous system by Treponema pallidum: implications for diagnosis and treatment.

Sheila A. Lukehart;Edward W. Hook;Sharon A. Baker-Zander;Ann C. Collier

736
Citations
CD4 nadir is a predictor of HIV neurocognitive impairment in the era of combination antiretroviral therapy.

Ronald J. Ellis;Jayraan Badiee;Florin Vaida;Scott Letendre

509
Citations
Safety of and immunological response to a recombinant vaccinia virus vaccine expressing HIV envelope glycoprotein

E. L. Cooney;E. L. Cooney;E. L. Cooney;A. C. Collier;A. C. Collier;A. C. Collier;P. D. Greenberg;P. D. Greenberg;P. D. Greenberg;R. W. Coombs;R. W. Coombs;R. W. Coombs

494
Citations
Prevalence and predictive value of intermittent viremia with combination hiv therapy.

Diane V. Havlir;Roland Bassett;Diane Levitan;Peter Gilbert

476
Citations
Safety, pharmacokinetics, and antiviral activity of AMD3100, a selective CXCR4 receptor inhibitor, in HIV-1 infection

Craig W. Hendrix;Ann C. Collier;Michael Marcel Lederman;Dominique Schols

465
Citations
Neurocognitive Change in the Era of HIV Combination Antiretroviral Therapy: The Longitudinal CHARTER Study

Robert K. Heaton;Donald R. Franklin;Reena Deutsch;Scott Letendre

446
Citations
Abacavir-lamivudine versus tenofovir-emtricitabine for initial HIV-1 therapy.

Paul E. Sax;Camlin Tierney;Ann C. Collier;Margaret A. Fischl

429
Citations
Neurologic relapse after benzathine penicillin therapy for secondary syphilis in a patient with HIV infection.

Carol Dawn Berry;Thomas M. Hooton;Ann C. Collier;Sheila A. Lukehart

428
Citations
A Randomized Controlled Trial of a Reduced Daily Dose of Zidovudine in Patients with the Acquired Immunodeficiency Syndrome

Margaret A. Fischl;Corette B. Parker;Carla Pettinelli;Michael Wulfsohn

421
Citations
Continued High Prevalence and Adverse Clinical Impact of Human Immunodeficiency Virus–Associated Sensory Neuropathy in the Era of Combination Antiretroviral Therapy: The CHARTER Study

Ronald J. Ellis;Debralee Rosario;David B. Clifford;Justin C. McArthur

406
Citations
Atazanavir Plus Ritonavir or Efavirenz as Part of a 3-Drug Regimen for Initial Treatment of HIV-1

Eric S. Daar;Camlin Tierney;Margaret A. Fischl;Paul E. Sax

396
Citations
Drug susceptibility in HIV infection after viral rebound in patients receiving indinavir-containing regimens.

Diane V. Havlir;Nick S. Hellmann;Christos J. Petropoulos;Jeannette M. Whitcomb

364
Citations

Frequent Co-Authors

David B. Clifford Washington University in St. Louis

Igor Grant University of California, San Diego

Benjamin B. Gelman The University of Texas Medical Branch at Galveston

Ronald J. Ellis University of California, San Diego

Susan Morgello Icahn School of Medicine at Mount Sinai

Justin C. McArthur Johns Hopkins University School of Medicine

Robert W. Coombs University of Washington

Scott Letendre University of California, San Diego

Robert K. Heaton University of California, San Diego

J. Allen McCutchan University of California, San Diego

External Links

Personal website of Ann C. Collier

If you think any of the details on this page are incorrect, let us know.

Related Online Degrees & Career Pathways

For those interested in merging immunology knowledge with advanced healthcare roles, pursuing a Nurse Practitioner degree can be a strategic path. Many students explore the easiest np program options to balance rigorous study with personal commitments, ensuring a smooth transition into the nursing field.

Specializations such as Psychiatric Mental Health Nurse Practitioner (PMHNP) programs offer focused clinical training and growing career opportunities. When researching the best fit, candidates often consider the top pmhnp programs known for their excellent clinical placement rates to gain practical experience crucial for success.

Cost is another important factor. Students frequently seek out the cheapest pmhnp programs to pursue quality education without overwhelming financial burden. Evaluating tuition and financial aid options can make advanced degrees more accessible.

Finally, understanding career outcomes is essential before commitment. Resources detailing dnp salary transparency provide valuable insights on earning potential across states, helping students align their education with long-term professional goals.